Stockscreener 앱 받기
41.54
1.68%
-0.71
시간 외 거래:
41.50
-0.04
-0.10%
Enliven Therapeutics Inc 주식(ELVN)의 최신 뉴스
ELVN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
The Technical Signals Behind (ELVN) That Institutions Follow - Stock Traders Daily
Biopharma Enliven joins TD Cowen, Jefferies investor chats online - Stock Titan
Enliven Therapeutics to Present at Upcoming Investor Conferences - Moomoo
ELVN News | ENLIVEN THERAPEUTICS INC (NASDAQ:ELVN) - ChartMill
Enliven Therapeutics CMO sells $198,971 in stock By Investing.com - Investing.com Australia
Enliven Therapeutics CMO sells $198,971 in stock - Investing.com
Enliven Therapeutics (ELVN) CMO trades 5,000 shares and exercises 5,000 options - Stock Titan
Enliven Therapeutics (NASDAQ: ELVN) proposed 15,000-share sale via Jefferies - Stock Titan
Polar Capital (ELVN) discloses 5.06M shares; 8.46% ownership reported - Stock Titan
Vestal Point / Ryan Wilder report 3.25M shares in Enliven Therapeutics (ELVN) - Stock Titan
Venrock group discloses 1.73M ELVN shares (2.8% of float) - Stock Titan
Fairmount files 13G/A: 1.86M shares (3.1%) in Enliven Therapeutics (ELVN) - Stock Titan
Commodore holds 4.8M shares in Enliven (NASDAQ: ELVN) after amendment - Stock Titan
Polar Capital (ELVN) discloses 5.07M shares, 8.47% stake in ENLIVEN - Stock Titan
JonesTrading Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $45 - Moomoo
Enliven Therapeutics (ELVN) Slips -3.15%, Testing $40.08 Support 2026-05-14Hot Stocks - newser.com
ELVN stock climbs as Guggenheim launches coverage with $80 price target ahead of conference data unveil - MSN
Precision Trading with Enliven Therapeutics Inc. (ELVN) Risk Zones - Stock Traders Daily
ELVN Stock Climbs As Guggenheim Launches Coverage With $80 Price Target Ahead Of Conference Data Unveil - Stocktwits
Enliven to present updated ELVN-001 leukemia trial data at EHA By Investing.com - Investing.com South Africa
Enliven to present updated ELVN-001 leukemia trial data at EHA - Investing.com Australia
Enliven Therapeutics Insiders Sell US$644k Of Stock, Possibly Signalling Caution - Moomoo
Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CML - PR Newswire
Guggenheim Initiates Coverage on Enliven Therapeutics With Buy, $80 Price Target - marketscreener.com
A Look At Enliven Therapeutics (ELVN) Valuation After Analyst Support And Phase 3 Trial Plans - Sahm
TradingKey - TradingKey
Guggenheim initiates Enliven Therapeutics stock with buy rating By Investing.com - Investing.com Canada
Guggenheim Initiates Enliven Therapeutics(ELVN.US) With Buy Rating, Announces Target Price $80 - Moomoo
Merck & Co. Inc. (MRK)Strategic Investment Implications from Clinical-Stage Oncology Pipeline DevelopmentsCompetitive Risk - newser.com
Why is Enliven Therapeutics (ELVN) One of the Best Performing Healthcare Stocks so Far in 2026? - Insider Monkey
Enliven Therapeutics Bolsters Board to Prepare for Next Phase of Development - Quantisnow
Enliven: Drug candidate ‘has the potential to be the best-in-class’ - BizWest
5 Best Performing Healthcare Stocks So Far in 2026 - Insider Monkey
Goldman Sachs Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Raises Target Price to $59 - Moomoo
Enliven Therapeutics, Inc. (ELVN) - DirectorsTalk Interviews
JonesTrading Initiates Enliven Therapeutics(ELVN.US) With Buy Rating, Announces Target Price $45 - Moomoo
Enliven Therapeutics : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) - marketscreener.com
Q1 2026: Enliven Therapeutics (NASDAQ: ELVN) narrows loss, holds $452M cash - Stock Titan
Enliven Therapeutics Q1 net loss narrows as R&D spending reduces - TradingView
Enliven Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Enliven Therapeutics (NASDAQ: ELVN) narrows loss and targets Phase 3 trial - Stock Titan
Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update - marketscreener.com
Terns Buyout Deal Ignites Optimism For Enliven Therapeutics’s Blood Cancer Portfolio - MSN
Enliven Therapeutics (ELVN) price target increased by 11.14% to 52.02 - MSN
Wall Street Zen Downgrades Enliven Therapeutics (NASDAQ:ELVN) to Sell - MarketBeat
Pictet Asset Management Holding SA Sells 94,852 Shares of Enliven Therapeutics, Inc. $ELVN - MarketBeat
Director sale notice — Enliven Therapeutics (NASDAQ: ELVN) files Form 144 - Stock Titan
2.98%
1.33%
자본화:
|
볼륨(24시간):